Skip to main content

NCI Sets Aside $35M to Create Cancer Genome Characterization Network Under TCGA Project

NEW YORK, March 13 (GenomeWeb News) - The National Cancer Institute has set aside $35 million in funding over the next three years to create a network of Cancer Genome Characterization Centers, or CGCCs, which will "generate diverse and complementary datasets and develop bioinformatics tools that support a rational approach for the selection of candidate genes and genomic regions for sequencing," according to NCI's request for applications.

 

The CGCC network is a component of The Cancer Genome Atlas (TCGA) Pilot Project that NCI and the National Human Genome Research Institute announced in December.

 

According to the RFA, the TCGA's centralized Human Cancer Biospecimen Core Resource will provide each CGCC with biomolecules obtained from highly annotated, quality-controlled human cancer biospecimens. The CGCCs are expected to use techniques that maximize genome coverage and resolution to provide optimal information on the cancer genome, epigenome, and transcriptome. 

 

"Each CGCC team will be expected to have achieved the operational capacity to conduct analyses at a minimum rate of 1,000 samples per year by the end of the first six months," the NCI RFA states. "It is anticipated that throughout the project each group will implement protocols that further enhance sample throughput capabilities, allowing throughput rates to exceed 1,000 samples each year in years 2 and 3 of the Pilot Project."

 

NCI said it intends to commit approximately $35 million for three years to fund up to four centers, with around $11.7 million allotted for 2006.

 

Letters of intent from interested parties are due April 12 and applications are due May 12.

 

The complete announcement is available here.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.